Laboratory assessment of antithrombotic therapy: What tests and if so why?

Pathophysiology of Haemostasis and Thrombosis

Volumn 27, Issue 5, 1997, Pages 211-218

  Kher, André ^a   Al Dieri, Raed ^b   Hemker, H Coenraad ^b   Béguin, Suzette ^b  

^a Euthemis   (France)

^b MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ARGATROBAN; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 10A INHIBITOR; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 9; HEPARIN; HIRUDIN; HIRULOG; LOW MOLECULAR WEIGHT HEPARIN; PROTEIN C; PROTEIN S; PROTHROMBIN; THROMBIN; THROMBIN INHIBITOR;

ANTICOAGULANT THERAPY; BLOOD CLOTTING TIME; DRUG MECHANISM; DRUG MONITORING; EDITORIAL; LABORATORY TEST; PARTIAL THROMBOPLASTIN TIME; PATHOGENESIS; PRIORITY JOURNAL; THROMBOPLASTIN TIME; THROMBOSIS;

ANTICOAGULANTS; DRUG MONITORING; HUMANS; LABORATORY TECHNIQUES AND PROCEDURES; THROMBOSIS;

EID: 0031402315     PISSN: 14248832     EISSN: 14248840     Source Type: Journal    
DOI: 10.1159/000217459     Document Type: Article

References (34)

1. Lcfkovits J, Topol EJ: Direct thrombin inhibitors in cardiovascular medicine. Circulation 1994;90: 1522-1536.
2. Fitzgerald GA: The human pharmacology of thrombin inhibition. Coron Artery'Dis 1996;7:911-918.
3. van-Bergen PF, Deckers JW, Jonker JJ, van Domburg RT, Azar AJ, Hof-man A: Efficacy of long-term anticoagulant treatment in subgroups of patients after myocardial infarction. Br Heart J 1995;74:117-121.
4. Azar AJ, Cannegicter SC, Deckers JW, Briet E, van Bergen PF, Jonker JJ, Roscndaal FR: Optimal intensity of oral anticoagulant therapy after myocardial infarction. J Am Coll Cardiol 1996;27:1349-1355.
5. Azar AJ, Deckers JW, Rcsendaal FR, van Bergen PF, van dcr Mccr FJ, Jonker JJ, Briet E: Assessment of therapeutic quality control in a long-term anticoagulant trial in post-myocardial infarction patients. Thromb Hacmost 1994;72:347-351.
6. Azar AJ, Koudstaal PJ, Wintzen AR, van Bergen PF, Jonker JJ, Deckers JW: Risk of stroke during long-term anticoagulant therapy in patients after myocardial infarction. Ann Neurol 1996;39:301-307.
7. Hirsh J. Dalen JE, Deykin D, Poller L, Bussey H: Oral anticoagulants. Mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 1995; 108(suppl):2318-2468.
8. Béguin S, Lindhout T, Hemker HC. et al: The mode of action of heparin in plasma. Thromb Haemost 1988; 60:457-462.
9. Béguin S, Dol F, Hemker HC: Factor 1 Xa inhibition contributes to the heparin effect. Thromb Hacmost 1991;66:306-309.
10. Kitchen S, Preston FE: The therapeutic range for heparin therapy: Relationship between six activated partial thromboplastin time reagents and two heparin assays. Thromb Haemost 1996;75:734-739.
11. D’Angelo A, Seveso MP. D’Angelo SV, Gilardoni F, Dettori AG, Bon-ini P: Effect of clot-detection methods and reagents on activated partial thromboplastin time (APTT). Am J Clin Pathol 1990;94:297-306.
12. Van der Velde EA, Poller L: The APTT monitoring of heparin-The ISTH/1CSH Collaborative Study. Thromb Haemost 1995;73:73-81.
13. Chiu HM. Hirsh J, Yung WL, Re-goeczi E, Gent M: Relationship between the anticoagulant and antithrombotic effects of heparin in experimental venous thrombosis. Blood 1977;49:171-184.
14. Basu D, Gallus A, Hirsh J, Cade JF: A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time. N Engl J Med 1972,287:324-327.
15. Hull RD, Raskob GE, Hirsh J: Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal vein thrombosis. N Engl J Med 1986,315:1109-1114.
16. Levine MN, Hirsh J, Gent M. Tur-pie AG, Cruickshank M. Weitz J, Anderson D, Johnson M: A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin. Arch Intern Med 1994;154:49-56.
17. Anand S, Ginsberg JS, Kearon C, Gent M, Hirsh J: The relation between the activated partial thromboplastin time response and recurrence in patients with venous thrombosis treated with continuous intravenous heparin. Arch Intern Med 1996;156:1677-1681.
18. Teien AN, Lie M: Heparin assay in plasma. A comparison of five clotting methods. Throm
19. Eika C, Go MHC, Kicrulf P: Detection of small amounts of heparin by the thrombin clotting time. Lancet 1972;vol ii:376.
20. Godal HC: The assay of heparin in thrombin systems. Scand J Clin Lab Invest 1961;13:153-166.
21. Soloway HB, Cox SP: In vitro comparison of the thrombin time and activated partial thromboplastin time in the laboratory control of heparin therapy. Am J Clin Pathol 1973;60:648-650.
22. Ts’ao C, Raymond J, Kolb T, Lo R: Effects of source and concentration of thrombin, and divalent cations, on thrombin time of heparinized plasma. Am J Clin Pathol 1976;65: 206-212.
23. Denson KW, Bonnar J: The measurement of heparin. A method based on the potentiation of antifactor Xa. Thromb Diath Haemorrh 1973;30:471-479.
24. Hattersley PG: Progress Report: The activated coagulation time of whole blood (ACT). Am J Clin Pathol 1976;66:899-904.
25. Blakely JA: A rapid bedside method for the control of heparin therapy. Can Med Assoc J 1968;99:1072-1076.
26. Forman WB, Bayer G: A simplified method for monitoring heparin therapy at the bedside: the activated whole blood clotting time. Am J He-matol 1981;11:277-281.
27. Nowak G, Bucha E: A new method for the therapeutical monitoring of hirudin. Thromb Haemost 1993;69: 1306-1314.
28. Esslinger HU, Dubbers K, Radziwon P, Breddin HK: Monitoring of the anticoagulant effects of PEG-hirudin administered as a continuous 24-hour infusion following an I. V. bolus injection in healthy volunteers using the ecarin clotting time. Thromb Haemost 1997; (suppl):277-278.
29. Bode C, Kohler B, Steg G, Parow C, Rubsamen K: The ecarin clotting time but not the aPTT is a reliable indicator for PEG-hirudin blood levels in patients with unstable angina pectoris. J Am Coll Cardiol 1997; 29:401A-411A.
30. Teien AN, Lie M, Abildgaard U: Assay of heparin in plasma using a chromogenic substrate for activated factor X. Thromb Res 1976;8:413-416.
31. Hcmkcr HC, Béguin S: The activity of heparin in the presence and absence of Ca" ions; why the anti-Xa activity of LMW heparins is about two times overestimated. Thromb Haemost 1993;70:717-718.
32. Walenga JM. Bara L, Samama M, Fareed J: Amidolytic antifactor Xa assays in the laboratory evaluation of heparin and low molecular weight fractions. Semin Thromb Haemost 1985;11:100-107.
33. Hemker HC, Béguin S: Thrombin generation in plasma: Its assessment via the endogenous thrombin potential. Thromb Haemost 1995;74: 134-138.
34. Widders S, Mukherjee M. Michicls J, Rijkcrs DTS, Cambus JP, Knebel RWC, Kakkar VV, Hemker HC, Béguin S: The routine determination of the endogenous thrombin potential. First results in different forms of hyper-and hypocoagulabil-ity. Thromb Haemost 1997;77:629-636.